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Abstract 8 
The window for acute ischemic stroke treatment was previously limited to 4.5 hours for 9 
intravenous tissue plasminogen activator and to 6 hours for thrombectomy. Recent studies using 10 
advanced imaging selection expand this window for select patients up to 24 hours from last known well. 11 
These studies directly affect emergency stroke management, including pre-hospital triage and 12 
emergency department management of suspected stroke patients. This narrative review summarizes 13 
the data expanding the treatment window for ischemic stroke to 24 hours and discusses these 14 
implications on stroke systems of care. It analyzes the implications on pre-hospital protocols to identify 15 
and transfer large vessel occlusion stroke patients, on issues of distributive justice, and on emergency 16 
department management to provide advanced imaging and access to thrombectomy centers. The 17 
creation of high-performing systems of care to manage acute ischemic stroke patients requires 18 
academic emergency physician leadership attentive to the rapidly changing science of stroke care. 19 
 20 
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 31 
Introduction 32 
Acute ischemic stroke in the United States is the fifth leading cause of death, the leading cause 33 
of preventable disability, and has an incidence of over 700,000 annual events.
1
 The treatment of acute 34 
ischemic stroke changed dramatically following the publication of the National Institute of Neurological 35 
Disorders and Stroke (NINDS) trials in 1995,
2
 which demonstrated improved outcomes for patients 36 
treated with intravenous tissue plasminogen activator (IV t-PA). Since then, national quality 37 
improvement efforts such as Get with the Guidelines-Stroke have sought to promote rapid stroke 38 
evaluation and IV t-PA delivery to appropriate patients.
3
  39 
Patients with acute ischemic stroke and large vessel occlusion (LVO) are at especially high risk of 40 
poor outcomes. They represent only one-third of all ischemic stroke cases, but LVO strokes are 41 
responsible for over 95% of acute ischemic stroke-related mortality and 60% of acute ischemic stroke-42 
related death or permanent dependency.
4
 Without emergent recanalization, 60 to 80% of LVO strokes 43 
result in death or permanent disability.
5,6
  Landmark trials published in 2015 used clinical and imaging-44 
based criteria to select LVO stroke patients for endovascular therapy and significantly changed the 45 
treatment landscape for acute ischemic stroke.
7-12
 These trials demonstrated endovascular therapy as a 46 
highly effective treatment for LVO stroke and revealed the potential for beneficial treatment beyond the 47 
4.5-hour IV t-PA treatment window.
12
  48 
Ongoing advancements in the imaging selection of stroke patients most likely to benefit from 49 
reperfusion therapies led to the conduct and recent publication of 3 trials in 2018 that are highly 50 
relevant to emergency care.
13-15
 They shift the paradigm of acute ischemic stroke treatment from time-51 
ďased to ͞tissue-ďased͟ treatŵeŶt decisioŶs. Tissue-based assessment determines salvageable brain 52 
tissue on advanced imaging rather than rigid treatment windows defined by time from last known 53 
well.
16
 This paper summarizes these trials and analyzes their potential impact on stroke systems of care. 54 
We analyze the impact on pre-hospital stroke care, on relevant issues of distributive justice, and on 55 
emergency department management. 56 
 57 
Thrombectomy Trials Expanding Treatment up to 24-Hours from Symptom Onset 58 
The DAWN
13
 and DEFUSE-3
14
 trials were prospective studies that randomized late-presenting 59 
patients with anterior LVO stroke to endovascular thrombectomy plus standard medical therapy versus 60 
standard medical therapy alone (table 1).  Both studies enrolled patients with a last known well time > 6 61 
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hours prior to presentation (6-24 hours for DAWN and 6-16 hours for DEFUSE-3). These studies utilized 62 
advanced imaging protocols to ensure the presence of LVO without large areas of core infarct. The 63 
primary outcome was the proportion of patients with functional independence at 90-days, defined as a 64 
modified Rankin score (mRS) score of 0 to 2. The DAWN trial also had a co-primary endpoint of the 65 
mean utility-weighted mRS, a patient-centered outcome using the mRS and a utility approach to quality 66 
of life.   67 
In these trials, subjects had major neurological deficits with small volume ischemic core on 68 
imaging at the time of enrollment. The trials defined the ischemic core by measurements using CT 69 
perfusion imaging and RAPID software (iSchemaView, Golden, CO). In DAWN, patients had to have a 70 
ŵisŵatch ďetǁeeŶ the voluŵe of the ischeŵic core aŶd cliŶical fiŶdiŶgs deterŵiŶed ďy the patieŶt’s 71 
NIHSS. In DEFUSE-3, patients had to have a ratio of ischemic tissue to infarct volume on perfusion 72 
imaging of 1.8 or greater. 73 
Both trials were stopped early when pre-specified interim analyses demonstrated significant 74 
benefit in the thrombectomy arm. Significantly higher rates of vessel recanalization at 24 hours were 75 
seen in the treatment groups compared to the control groups (77% versus 39% in DAWN, p<0.001; 78% 76 
versus 18% in DEFUSE-3, p<0.001). Recanalization translated to improved functional outcomes between 77 
treatment and control groups.  In DAWN, the mean score for the utility-weighted mRS at 90 days was 78 
significantly higher in the thrombectomy group as compared to the control group (adjusted difference 79 
2.0 points, 95% CI 1.1 to 3.0), indicating more favorable outcomes. In DEFUSE-3, endovascular treatment 80 
was associated with a favorable shift in the distribution of mRS at 90 days (odds ratio 2.77, p<0.001). 81 
Patients treated with thrombectomy had substantially higher rates of functional independence (mRS 0-82 
2) at 90 days, resulting in a very low number needed to treat (NNT) for benefit in both studies (Table 1).     83 
 84 
Expanding IV t-PA Treatment Past 4.5-Hours 85 
Both DAWN and DEFUSE-ϯ had suďstaŶtial Ŷuŵďers of participaŶts ǁith ͞ǁake-up͟ strokes (6ϯ% 86 
and 53% respectively) in the thrombectomy groups. Wake-up strokes are those in which a patient 87 
awakens with stroke symptoms, but whose last known normal time was before going to sleep. These 88 
patients have historically been excluded from IV-t-PA treatment due to inability to determine the true 89 
time of onset for their stroke. Furthermore, many patients with wake-up strokes do not have an LVO. 90 
The recently published WAKE-UP
15
 study was a randomized, double-blind controlled trial comparing IV t-91 
PA versus placebo among ischemic stroke patients with unknown time of onset and stroke recognized > 92 
4.5 hours prior to presentation. Patient eligibility required emergent magnetic resonance imaging (MRI) 93 
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and abnormal signal on diffusion weighted imaging (DWI) with no visible signal change on fluid-94 
attenuated inversion recovery (FLAIR) imaging. Prior research demonstrated that this DWI-FLAIR 95 
mismatch indicates an onset time within the past 4 to 5 hours.
17
 Major inclusion/exclusion criteria as 96 
well as characteristics of the IV t-PA group are summarized in Table 1.   97 
The trial was stopped early due to cessation of funding with 503 of the planned 800 patients 98 
enrolled. Patients with favorable DWI-FLAIR mismatch that received IV t-PA were significantly more 99 
likely to have a favorable outcome, defined as a mRS score of 0 or 1 at 90 days (adjusted odds ratio 1.61, 100 
95% CI 1.09 to 2.36).
15
 There was no significant difference in symptomatic intracranial hemorrhage, 101 
though there was a higher rate of the most severe form of radiologically-classified hemorrhage, 102 
parenchymal hemorrhage type 2, in the IV t-PA group (Table 1, p=0.03).
18,19
  There was also a non-103 
significant trend toward higher mortality rates in the IV t-PA cohort (adjusted odds ratio 3.38, 95% CI 104 
0.92 to 12.52).               105 
 106 
The ExpaŶded TreatŵeŶt WiŶdow’s Iŵpact oŶ Pre-Hospital Stroke Care 107 
The trials discussed above expand the treatment window to select patients. To translate these 108 
findings into clinical practice necessitates change to existing methods of patient selection and triage. 109 
Here we discuss the pre-hospital implications in re-engineering stroke systems of care. Thrombectomy is 110 
time-sensitive and is only available at a limited number of stroke centers.
20,21
 Rapid identification and 111 
direct transport of LVO patients in the field to thrombectomy-capable hospitals has the potential to 112 
improve patient outcomes. To do so, however, requires accurate identification of patients with LVO 113 
stroke in the pre-hospital setting.  114 
Despite derivation of more than 30 different stroke severity tools for this purpose, most have 115 
not been prospectively validated in the field, and diagnostic performance has been highly variable.
22,23
 116 
The most rigorously studied LVO prediction tools include the Cincinnati Pre-Hospital Stroke Severity 117 
Scale (CPSSS), the Los Angeles Motor Score (LAMS), and Rapid Arterial Occlusion Evaluation (RACE).
24-27
 118 
Based on pre-hospital data alone, sensitivities for these tools range from 38% to 76%, specificities range 119 
from 72% to 87%, and none demonstrate clear superiority.
22
  Table 2 demonstrates the accuracy of the 120 
common decision aid tools based on pooled data from a recent metaanalysis.
22
 The test characteristics 121 
of these tools vary substantially due to differences in the amount and type of data collected on 122 
neurological symptoms. The LAMS tool, for instance, only collects data on 3 aspects of motor function, 123 
whereas the NIHSS collects 13 data points on sensory, motor, ocular, and executive function. Current 124 
evidence suggests that all scales are at risk of both under- and over-triage of LVO stroke patients. It is 125 
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not clear that clinical assessment-based pre-hospital assessments will adequately capture the 126 
heterogeneity of LVO stroke presentations. 127 
 To address the complex decision making around pre-hospital bypass decisions, the American 128 
Heart AssociatioŶ’s MissioŶ: LifeliŶe Stroke coŵŵittee puďlished a coŶseŶsus pre-hospital triage 129 
algorithm for use by regional stroke systems.
28
 According to this protocol, pre-hospital providers screen 130 
patients with suspected stroke using one of 3 stroke severity tools (CPSSS, RACE, LAMS). They then 131 
transport patients with a positive LVO screen directly to a thrombectomy-capable center if the patient is 132 
within 6 hours of last known well and bypassing a closer ED would add less than 15-minutes to transport 133 
time. The real-world impact of such an algorithm is largely unknown, although a randomized controlled 134 
trial (RACECAT) using this strategy is ongoing.
29
  135 
In light of the recent trials expanding the thrombectomy treatment window to 24 hours, the 6-136 
hour limit in such protocols requires reexamination. Bypassing stroke ready hospitals and primary stroke 137 
centers up to 24-hours after symptom onset may expedite therapy for those patients who meet 138 
thrombectomy criteria. Indeed, inter-hospital transfer is associated with onset-to-revascularization 139 
delays averaging more than 100 minutes.
30
 However, such bypass protocols could also negatively impact 140 
care by placing patients farther from their families and overwhelming the stroke response systems of 141 
comprehensive stroke centers with patients who are not candidates for intervention.  142 
Even if pre-hospital stroke assessment tools improve substantially in identifying LVO in the 143 
extended 6 to 24-hour time frame, many of these patients will ultimately not qualify for thrombectomy 144 
based on the selective imaging criteria in DAWN and DEFUSE-3.
31
 Development of bypass protocols that 145 
address such challenges while still ensuring rapid access to thrombectomy for eligible patients is a major 146 
research need. In the interim, pre-hospital triage algorithms require the input of emergency physicians 147 
for local consideration of EMS capacity, transport distances, and hospital resources to design regional 148 
protocols that maximize access to thrombectomy for appropriate candidates while minimizing wasteful 149 
resource utilization.  150 
 151 
Issues of Distributive Justice in Changing Stroke Systems of Care to Expand the Treatment 152 
Window  153 
The ethics of distributive justice address the balance between benefits and burdens within a 154 
population.
32
 When considering triage and management of potential LVO stroke patients, there exists a 155 
balance between providing the greatest benefit to these patients while limiting burdens to the 156 
remaining population of patients seeking emergency medical care at a single site or within a larger 157 
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system. As noted above, bypassing of closer hospitals for potential LVO patients can also strain patient 158 
families, consume prehospital resources, and overwhelm academic stroke centers with non-159 
thrombectomy candidates. 160 
The ethical conflicts arise between the utilitarian goal to do the greatest good for the greatest 161 
number and the principles of nonmaleficence and equal respect for all.
33
 Triage decisions become 162 
challenging when a condition is life-threatening and a life-saving resource is scarce, such as occurs in 163 
disaster situations. In the case of thrombectomy, the scarcity of the resource is rapidly changing. Using 164 
2011 data, 56% of people within the United States had access by ground to endovascular-capable 165 
hospitals within 60-minute transport time.
21
 By air transport, this proportion increased to 85%. As health 166 
systems create referral patterns and increase their capacity to perform emergent thrombectomy, the 167 
scarcity of endovascular care will shrink. Likewise, the scarcity of emergent MRI may shrink and provide 168 
added treatment capacity for patients without LVO who present > 4.5 hours from last known well. 169 
Thrombectomy for eligible LVO stroke patients is one of the most impactful, evidence-based 170 
emergency medical interventions. Hence, relative to many other emergent diagnoses and interventions, 171 
there should be a higher rate of tolerance for false positives in screening and for relocating resources 172 
from other sick patients. Such tolerance is dependent on the values communities hold and operational 173 
decisions by health systems.  174 
 175 
The ExpaŶded TreatŵeŶt WiŶdow’s Iŵpact oŶ Emergency Department and Hospital Stroke 176 
Readiness 177 
At the ED and hospital level, operational decisions largely fall within their stroke care 178 
designations. The Joint Commission began designating Primary Stroke Centers (PSC) in 2004. The PSC 179 
was required to demonstrate compliance with specific quality measures and demonstrate a minimum 180 
number of strokes that were treated with IV t-PA or thrombectomy.
34
 Subsequently, the Joint 181 
Commission also began recognizing centers capable of providing more advanced stroke care, defined as 182 
Comprehensive Stroke Centers (CSC).
35
 Beyond PSC requirements, CSCs provide neurocritical care, 24/7 183 
access to advanced imaging, endovascular procedure capability, and on-site neurosurgical providers.  184 
Recently, the Joint Commission also began certifying Thrombectomy Capable Hospitals (TCHs).
36
 185 
These represented an intermediary between CSCs and PSCs and originally required physician-specific 186 
certification to perform acute stroke thrombectomy and minimum procedural volumes. Nevertheless, in 187 
September 2018, the Joint Commission suspended physician training and volume requirements for both 188 
CSC and TCH hospitals.
37
 Interventional experts in acute stroke therapy raised concern over this change, 189 
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noting that evidence to support good outcomes for LVO patients is lacking when thrombectomy is 190 
performed by low-volume hospitals.
38
 Centers with higher volumes and ongoing quality improvement 191 
processes demonstrate faster door-to-treatment time for thrombectomy and excellent outcomes in 192 
prior trials.
39-41
 While TCHs have the potential to lower times to treatment in geographic locations where 193 
CSCs are sparse, striking the right balance between access and adequate expertise in LVO management 194 
requires further investigation.  195 
The advances in stroke therapy have created an imperative for EDs to establish protocols to 196 
identify acute ischemic stroke patients who might benefit from reperfusion therapies. This includes 197 
screening protocols for LVO for patients up to 24 hours past their last known well time. Many EDs have 198 
developed protocols for patients who present within 6 hours since last known well, but the results of 199 
DEFUSE 3 and DAWN broaden the challenge of screening many more patients up to 24 hours from onset 200 
of symptoms.
42
 Some EDs have implemented broad screening protocols that include performance of CT 201 
angiography (CTA) in every code stroke patient.
43
 Other systems perform CTA selectively, based on 202 
cliŶical criteria such as a LAMS score ≥ ϰ or NIHSS ≥ 6.44 Data indicate that use of a NIHSS ≥ 6 to select 203 
patients for CTA has 80% sensitivity and 72% specificity for predicting LVO.
22
  204 
In addition to expanding the pool of stroke patients who require screening for LVO, the results 205 
of DAWN and DEFUSE-3 have implications for the imaging techniques required.  These trials used 206 
perfusion imaging to determine infarct size and perfusion mismatch with RAPID software.
13,14
 While 207 
RAPID software performs automated calculation of the ischemia to infarct ratio on CT perfusion, it 208 
should be noted that such a calculation can be accomplished without proprietary software and that MRI 209 
with MRI perfusion is an alternative screening methods.
42
  Figure 1 demonstrates CT perfusion images 210 
with RAPID software calculation in a patient with a LVO that stands to benefit from thrombectomy. The 211 
perfusion mismatch ratio is 7.9, indicating a significant volume of hypoperfused tissue relative to 212 
infarcted tissue. If perfusion imaging is not available, transfer to a facility that can perform appropriate 213 
imaging and thrombectomy should be considered. The AHA guidelines endorse telemedicine with stroke 214 
teams to assist in the processes around advanced imaging and transfer criteria.
42
  215 
Health systems are beginning to test protocols to optimally manage wake-up stroke patients. 216 
Many stroke patients with unknown onset outside the traditional 4.5-hour treatment window may be 217 
candidates for IV t-PA. Nevertheless, based on the WAKE-UP study protocol, determination of eligibility 218 
requires estimation of the diffusion-flair mismatch on MRI. Fewer EDs have emergent MRI capacity 219 
compared to CTA and CT perfusion imaging. There is a need for further research to determine the real-220 
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world application of the WAKE-UP protocol and to determine if select wake-up patients benefit from 221 
transfer when emergent MRI is not available at a presenting ED.  222 
The complex decision-making involved in managing patients eligible for the time-sensitive 223 
interventions of IV t-PA and thrombectomy requires well-orchestrated systems of care. Development of 224 
clear protocols for EDs without thrombectomy capacity includes simplified decisions for advanced 225 
imaging, transfer decisions, and use of telemedicine. Many tertiary hospital systems have associations 226 
with smaller community sites that refer stroke patients to the hub hospital. Institutions not affiliated 227 
with a tertiary hospital should develop relationships with PSC and CSC hospital systems to develop 228 
protocols for the evaluation and transfer process for complex stroke patients who require higher levels 229 
of care.
45
 Academic emergency physicians at the PSC and CSC sites can be instrumental in fostering 230 
these relationships and developing well-orchestrated systems of care. 231 
 232 
Conclusions 233 
The expansion of the stroke treatment window based on advanced imaging criteria represents 234 
important advances in acute ischemic stroke therapy. Emergency physicians have significant leadership 235 
responsibilities in creating optimal systems of care. These responsibilities include leadership of medical 236 
control and pre-hospital protocols. They also include ED workflow, transport of select patients, and 237 
management within CSCs that have growing volumes of high-acuity stroke patients. Emergency 238 
physician guidance is critical in adapting the current science to improve systems of care and outcomes of 239 
acute ischemic stroke patients. 240 
 241 
 242 
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Table 1. Comparing recent trials of extended treatment windows for acute stroke patients* 
 DAWN
13
 DEFUSE-3
14
 WAKE-UP
15
 
Intervention vs Standard Care Thrombectomy Thrombectomy IV t-PA 
Enrollment Window, hours 6-24 6-16 > 4.5 
 
Median time from randomization, 
hours (IQR) 
12.2 (10.2-16.3) 10.9 (8.8-12.3) 10.3 (8.1-12.0) 
Age Limit, years  18 18-90 18-80 
 Mean/Median age ( SD; IQR) 69.4 ( 14.1) 70 (59-79) 65.3 ( 11.2) 
Lower Limit of Baseline NIHSS  10  6 > 0 
 Median Baseline NIHSS (IQR) 16 (10-20) 17 (13-21) 6 (4-9) 
Pre-existing Disability Limit, mRS ч 1 ч 2 ч 1 
Upper Limit of Infarct Volume, mL < 51 < 70 NA 
 
Median volume of ischemic core, ml 
(IQR) 
7.6 (2.0-18.0)
 
9.4 (2.3-25.6) 2.0 (0.8-7.9)
 
 Ratio of ischemic tissue to infarct core 
Clinical 
mismatch
ƚ
 
≥ 1.8 NA 
Functional Independence at 90 Days    
 Intervention Group vs Control 49% vs 13% 45% vs 17% 53% vs 42% 
 Number Needed to Treat (95% CI) 3 (2-4) 4 (3-7) 9 (5-36) 
Safety Outcomes, intervention vs control    
 Death at 90 days 19% vs 18%
 
14% vs 26% 4.1% vs 1.2% 
 Parenchymal hematoma Type 2 1.9% vs 1.0% 9% vs 3% 4.0% vs 0.4% 
*Characteristics and results presented of treatment groups only, except where indicated. The enrollment window 
as measured from the last known normal time. Functional independence defined as a mRS of 0-2 in DAWN and 
DEFUSE-3 but 0-1 in WAKE-UP. Parenchymal hematoma Type 2 is defined as an intracerebral hemorrhage involving 
more than 30% of the infarcted area with a substantial space-occupying effect or that is remote from the original 
infarcted area. VS, versus; IQR, interquartile range; SD, standard deviation; NIHSS, National Institutes of Health 
Stroke Scale; mRS, modified Rankin scale; NA, not applicable; CI, confidence interval.  
ƚ CliŶical ŵisŵatch categorized iŶ ϯ groups: A, age ≥ 8Ϭ years, NIHSS ≥ ϭϬ, iŶfarct voluŵe < Ϯϭ ŵL; B, age < 8Ϭ years, 
NIHSS ≥ ϭϬ, iŶfarct voluŵe < ϯϭ ŵL; C, age < 8Ϭ years, NIHSS ≥ ϮϬ, iŶfarct voluŵe < 5ϭ ŵL.  
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Table 2. Pre-hospital clinical decision aids for triaging suspected large vessel occlusion stroke patients
23-
27 
 NIHSS* RACE CPSSS LAMS 
Items Scored 13 6 3 3 
Score threshold ≥ 6 ≥ 5 ≥ 2 ≥ 4 
Sensitivity for LVO, % (95% CI) 80 (0.75–0.85) 69 (0.46–0.85) 56 (0.50–0.63) 38 (0.08–0.81) 
Specificity for LVO, % (95% CI) 72 (0.70–0.74) 81 (0.67–0.90) 82 (0.73–0.89) 87 (0.49–0.98) 
Area Under the Curve 0.80 0.77 0.72 0.70 
* NIHSS, National Institute of Health Stroke Scale; RACE, Rapid Arterial Occlusion Evaluation; CPSSS, Cincinnati Pre-
Hospital Stroke Severity Scale; LAMS, Los Angeles Motor Score (LAMS); LVO, large vessel occlusion; CI, confidence 
interval; For AUC, 95% CI not available.  
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